AcelRx Pharmaceuticals have announced that they will be hosting a key opinion leader (KOL) panel discussion virtually to explore its lead candidate Niyad for use as an anticoagulant in dialysis circuits.
The panel, which is taking place on 6 December 2023 at 11.am ET/8am PT, will include thought-leaders from both nephrology and critical care disciplines—Laurence Busse (Emory University School of Medicine, Atlanta, USA) and David W Boldt (UCLA Medical Center, Los Angeles, USA)—both of whom are also co-authors on a recent market research manuscript that reports current problems with anticoagulants when used in dialysis circuits.
They will also be discussing the study protocol for the upcoming Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy (NEPHRO CRRT) study, which will compare a placebo to Niyad for use in dialysis circuit anticoagulation, and is planned to begin later this year.
For further information or to register for this virtual event, click here.
